Company Overview and News
Hexcel (HXL - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
Textron (TXT) is a renowned name in the aerospace and defense industry. It operates five segments: aviation, bell, systems, industrial and finance. The firm has a posted 4%+ average in sales growth for the last five years, along with good fundamentals. In its latest quarter, revenue was up in the aviation, bell and industrial segments which was partially offset by from lower revenues in systems segment.
GD HXL HXL HRS TXT
It is not every day that a U.S. company transfers technology onto European soil. This time, the move gives the continent’s commercial aircraft industry complete autonomy for a key resource—carbon fiber. And it can be seen as a fair return. Hexcel Corp., the Stamford, Connecticut-based composite materials specialist, has just opened an integrated factory in Salaise-sur-Sanne, near Lyon, and has benefited from the region’s deep-rooted know-how in weaving since it took over .
AAR Corp. (AIR - Free Report) reported first-quarter fiscal 2019 adjusted earnings of 54 cents per share, which surpassed the Zacks Consensus Estimate of 52 cents by 3.9%. The adjusted figure reflected a year-over-year improvement of 63.6% from 33 cents registered in the year-ago quarter.
AAALY HXL HXL RTN AIR TXT AAALF
2018-08-19 seekingalpha - 4
SQ Advisors has just eleven positions. The top three holdings are CarMax, Allison Transmission, and Brookfield Asset Management, and they add up to ~36% of the entire portfolio.
KMX LBTY HXL ALSN CAXPF TYLE CHTR LBTYK TYL LILAB AAPL BAM LBRDB CABO BAMGF BBU LBTYB AXTA LBTYA LBRDK BRK.A SCHW HXL LILAK LBRDA SBAC BAMKF LILA
Both the aerospace as well as the defense industry are attractive for investors. Companies from both industries have created a lot of value for shareholders in the past, and both will benefit from long-term growth trends over the coming decades.
LMT NOC GD HXL HXL UTX COL ITA
Spirit Aerosystems Holdings, Inc. (SPR - Free Report) , a designer and manufacturer of aero structures for both commercial and defense aircraft, is set to release second-quarter 2018 results on Aug 1, before the opening bell. Increased demand for Boeing’s 737 and Airbus’s A350 jets is expected to boost Spirit AeroSystems’ second-quarter revenues. However, contributions from higher production rates, expected to boost bottom line in late 2018, are projected to hurt quarterly earnings this time.
LMT ALGN SPR HXL HXL TXT
Rockwell Collins Inc. (COL - Free Report) reported financial results for third-quarter fiscal 2018 (ended Jun 30, 2018). The company’s adjusted earnings per share of $1.73 lagged the Zacks Consensus Estimate of $1.89 by 8.5%. Reported earnings, however, grew 5.5% from $1.64 per share a year ago. Excluding the one-time items, the company reported GAAP earnings per share of $1.66 in the reported quarter, which increased 48.
LMT HXL HXL GNC XL XLGLF COL TXT
Leidos Holdings, Inc. (LDOS - Free Report) posted second-quarter 2018 adjusted earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.05 by 6.7%. The reported number also increased 7.7% from the year-ago figure of $1.04. The company reported GAAP earnings per share of 94 cents in the reported quarter, which increased 46.9% from the year-ago figure of 64 cents. Total Revenues Leidos Holdings posted total revenues of $2,529 million in the quarter, which lagged the Zacks Consensus Estimate of $2,563 million by 1.
LMT HXL HXL NVR TXT LDOS TRN SAM
STAMFORD, Conn., July 27, 2018 (GLOBE NEWSWIRE) -- Hexcel Corporation (NYSE:HXL) announced today that its Board of Directors has designated Jeffrey C. Campbell to serve as its independent Lead Director. Mr. Campbell succeeds Hexcel’s current independent Lead Director, W. Kim Foster, who is retiring from the Board for health reasons.
MCK HXL FTI.WI HXL FMC
Curtiss-Wright Corporation (CW - Free Report) reported second-quarter 2018 adjusted earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.28 by 40.6%. The reported figure is also higher than the year-ago quarter’s adjusted earnings of $1.21 by 48.8%. The year-over-year upside in earnings was driven by higher operating income, lower interest expense and a lower tax rate, as well as a slightly lower share count.
LMT HXL HXL CW TXT
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EPA:HXL / HEXCEL on message board site Silicon Investor.
|Hexcel (HXL)||Hexcel (HXL)||Hexcel (HXL)|